D arthritis in patients with an inadequate response to traditional diseasemodifying antirheumatic drugs or to an antitumour necrosis issue agent: a metaanalysis. Ann Rheum Dis 2011, 70:26671. 20. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP: Indirect comparison of tocilizumab and other biologic agents in individuals with rheumatoid arthritis and inadequate response to diseasemodifying antirheumatic drugs. Semin Arthritis Rheum 2010, 39:42541. 21. Singh JA, Christensen R, Wells GA, SuarezAlmazor ME, Buchbinder R, LopezOlivo MA, Ghogomu ET, Tugwell P: A network metaanalysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009, 181:78796. 22. Nixon RM, Bansback N, Brennan A: Working with mixed treatment comparisons and metaregression to carry out indirect comparisons to estimate the efficacy of biologic treatment options in rheumatoid arthritis. Stat Med 2007, 26:1237254. 23. Jadad A, Moore A, Carroll D, Jenikson C, Reynols J, Gavaghan D, McQuay H: Assessing the high-quality of reports of randomized clinical trials: is blinding necessary Manage Clin Trials 1996, 17:12. 24. Wells G, Li T, Maxwell L, MacLean R, Tugwell P: Determining the minimal clinically vital differences in activity, fatigue, and sleep quality in sufferers with rheumatoid arthritis. J Rheumatol 2007, 34:28089. 25. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA: Minimum essential difference amongst patients with rheumatoid arthritis: the patient’s point of view. J Rheumatol 1993, 20:55760. 26. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM: Clinical significance of changes in chronic pain intensity measured on an 11point numerical discomfort rating scale. Discomfort 2001, 94:14958. 27. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, et al: Interpreting the clinical importance of therapy outcomes in chronic discomfort clinical trials: IMMPACT recommendations.Formula of 6-Bromo-8-fluoroisoquinoline J Discomfort 2008, 9:10521. 28. Fries JF, Spitz PW, Young DY: The dimensions of well being outcomes: the wellness assessment questionnaire, disability and discomfort scales. J Rheumatol 1982, 9:78993. 29. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC: Interpreting indirect treatment comparisons and network metaanalysis for healthcare decision generating: report with the ISPOR Job Force on Indirect Therapy Comparisons Fantastic Analysis Practices: element 1.Price of 774212-81-6 Worth Wellness 2011, 14:41728.PMID:24463635 30. Lu G, Ades AE: Mixture of direct and indirect proof in mixed therapy comparisons. Stat Med 2004, 23:3105124. 31. Caldwell DM, Ades AE, Higgins JP: Simultaneous comparison of various therapies: combining direct and indirect evidence. BMJ 2005, 331:89700.Jansen et al. Overall health and High quality of Life Outcomes 2014, 12:102 http://www.hqlo.com/content/12/1/Page 14 of32. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A: Conducting indirecttreatmentcomparison and networkmetaanalysis research: report with the ISPOR Job Force on Indirect Therapy Comparisons Excellent Research Practices: aspect two. Value Wellness 2011, 14:42937. 33. Sutton AJ, Abrams KR: Bayesian solutions in metaanalysis and evidence.